ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2026
[Pathophysiological mechanisms of coagulation dysfunction associated with liver disease].
Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Coagulation abnormalities associated with liver diseases easily lead to spontaneous and secondary bleeding, which is associated with hemodynamic changes, reduced synthesis of coagulation factors, liver disease-related thrombocytopenia, and pharmacological interventions. On the other hand, patients with liver disease also have a hypercoagulable state, making them prone to portal vein thrombosis, which is associated with hemodynamic changes, reduced synthesis of anticoagulants, abnormal vascular intima structure, inflammation, and pharmacological treatment. Additionally, patients with liver disease are at an intertwined risk of bleeding and thrombosis and are in a fragile state of hemostasis rebalancing for an extended period. Genetic factors and diagnostic and therapeutic procedures further challenge the management of coagulation function in patients with liver disease. This article discusses the mechanisms of coagulation abnormalities from the perspectives of both bleeding and thrombosis, providing assistance for dynamically managing and rebalancing the hemostasis in patients with liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.